542 related articles for article (PubMed ID: 11344532)
1. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.
Bu HZ; Magis L; Knuth K; Teitelbaum P
Rapid Commun Mass Spectrom; 2001; 15(10):741-8. PubMed ID: 11344532
[TBL] [Abstract][Full Text] [Related]
2. High-throughput cytochrome P450 inhibition screening via cassette probe-dosing strategy. IV. Validation of a direct injection on-line guard cartridge extraction/tandem mass spectrometry method for simultaneous CYP3A4, 2D6 and 2E1 inhibition assessment.
Bu HZ; Knuth K; Magis L; Teitelbaum P
Rapid Commun Mass Spectrom; 2000; 14(20):1943-8. PubMed ID: 11013424
[TBL] [Abstract][Full Text] [Related]
3. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
[TBL] [Abstract][Full Text] [Related]
4. High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy. I. Development of direct injection/on-line guard cartridge extraction/tandem mass spectrometry for the simultaneous detection of CYP probe substrates and their metabolites.
Bu HZ; Magis L; Knuth K; Teitelbaum P
Rapid Commun Mass Spectrom; 2000; 14(17):1619-24. PubMed ID: 10960916
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
6. High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy. II. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP2D6 inhibition assessment.
Bu HZ; Magis L; Knuth K; Teitelbaum P
J Chromatogr B Biomed Sci Appl; 2001 Apr; 753(2):321-6. PubMed ID: 11334347
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Grimm SW; Dyroff MC
Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
[TBL] [Abstract][Full Text] [Related]
8. High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy: III. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP2C19 inhibition evaluation.
Bu HZ; Knuth K; Magis L; Teitelbaum P
J Pharm Biomed Anal; 2001 Jun; 25(3-4):437-42. PubMed ID: 11377023
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS.
Di L; Kerns EH; Li SQ; Carter GT
Int J Pharm; 2007 Apr; 335(1-2):1-11. PubMed ID: 17137735
[TBL] [Abstract][Full Text] [Related]
10. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
11. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
12. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
[TBL] [Abstract][Full Text] [Related]
13. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.
Yao M; Zhu M; Sinz MW; Zhang H; Humphreys WG; Rodrigues AD; Dai R
J Pharm Biomed Anal; 2007 May; 44(1):211-23. PubMed ID: 17418993
[TBL] [Abstract][Full Text] [Related]
14. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
[TBL] [Abstract][Full Text] [Related]
16. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
17. A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes.
Bhoopathy S; Xin B; Unger SE; Karnes HT
J Pharm Biomed Anal; 2005 Apr; 37(4):739-49. PubMed ID: 15797796
[TBL] [Abstract][Full Text] [Related]
18. Liquid chromatography/tandem mass spectrometry method for simultaneous evaluation of activities of five cytochrome P450s using a five-drug cocktail and application to cytochrome P450 phenotyping studies in rats.
Zhang S; Song N; Li Q; Fan H; Liu C
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Aug; 871(1):78-89. PubMed ID: 18614408
[TBL] [Abstract][Full Text] [Related]
19. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. V. Validation of a direct injection/on-line guard cartridge extraction--tandem mass spectrometry method for CYP1A2 inhibition assessment.
Bu HZ; Knuth K; Magis L; Teitelbaum P
Eur J Pharm Sci; 2001 Feb; 12(4):447-52. PubMed ID: 11231111
[TBL] [Abstract][Full Text] [Related]
20. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
Spracklin DK; Thummel KE; Kharasch ED
Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
